Beyfortus® For Prevention of Respiratory Syncytial Virus (RSV) in Infants

• 2024

  Log in to bookmark this resource.

  Log in

---

Access Resources

• Job AidEN
• Ask aRCie About This Resource

About

This webpage provides a pharmacy update on the use of Beyfortus for the prevention of RSV in infants. The FDA approved nirsevimab for infants and an RSV vaccine for mothers last year. Real-world studies show nirsevimab is 80-90% effective in preventing RSV-related hospitalizations. Partners for Kids offers resources for nirsevimab administration. Nirsevimab is recommended for infants < 8 months and at-risk children 8-19 months. Dosing depends on weight and age. Nirsevimab is available through the VFC Program at no cost for eligible patients.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Infant; Pediatrics; Pharmacies; Pharmacy; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Immunization Programs; Antibodies, Monoclonal, Humanized

Institutions: Nationwide Children's Hospital

---

More like this

Hospital Guidelines for Management of Pediatric Patients in Disasters 2015 · Northwest Healthcare Response Network Job Aid: High Flow Nasal Cannula (HFNC) 2022 · Seattle Children's Hospital Pediatric & Neonatal Disaster/Surge Guide 2022 · Ann and Robert H. Lurie Children’s Hospital, Illinois EMS for Children (EMSC)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---